UGA & Manus Among Awardees in $214M BioMADE Investment

BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

With funding from the U.S. Department of War and the U.S. National Science Foundation, these projects will support the production of critically needed goods and materials, strengthen the domestic supply chain, and build a 21st century workforce.


MINNEAPOLIS-ST. PAUL, MN/EMERYVILLE, CA, April 29, 2026 – Today, BioMADE announced 14 cutting-edge new projects that will support the growth and development of the U.S. bioindustrial manufacturing industry. These projects will support the manufacture of innovative bio-based products like a lithium biosorbent for biomining; plastics for 3D printing; proteins for wound healing and chemical defense; biosensors for disease detection; and more. They will leverage state-of-the-art methodologies like machine learning, AI, and advanced new sensors and purification systems. Projects will also support the development of the needed biomanufacturing workforce through projects that are easing the transition for veterans into civilian careers, launching community college programs, and developing hands-on apprenticeship programs. 


“Global competition for bioindustrial manufacturing is at a critical tipping point, with many countries around the world investing heavily in biotechnology innovation and commercialization. If the U.S. is to remain competitive, we must do the same,” said Douglas Friedman, Chief Executive Officer at BioMADE. “We appreciate U.S. Department of War and the National Science Foundation’s continued support for domestic biomanufacturing and their steadfast commitment to establishing the U.S. as a global leader in the 21st century bioeconomy through BioMADE." 


These projects represent a shared investment of over $21 million across 23 different member organizations that are located across the country – from the coasts to the heartland – highlighting the breadth and depth of the rapidly growing U.S. bioeconomy. 


"BioMADE's newest projects showcase the dual importance of bioindustrial manufacturing and its benefits to both the commercial and defense sectors," said Stephen Recchia, Program Manager for the Department of War Manufacturing Innovation Institutes. "Bioindustrial manufacturing has the power to secure domestic supply chains for essential chemicals and materials, enhance national security by reducing reliance on foreign inputs, and enable point-of-need manufacturing for warfighters." 


For the first time, some of these projects are funded through a partnership with the National Science Foundation, which will support initial efforts from the basic research through proof-of-concept, with BioMADE supporting technology maturation, risk reduction, and scale-up aspects of each integrated project. 


"Fundamental biological and biomanufacturing research supported by NSF has led to advances in health, food, fuels and chemicals," said Susan Marqusee, NSF Assistant Director for Biological Sciences. "These new projects build on NSF's long-term investment and help us to further economic growth in industrial biotechnology — a sector that contributes over $200 billion to the U.S. economy." 


"By connecting academic researchers with BioMADE's industry members, this public-private collaboration will help realize the potential of fundamental science and engineering research for food, health, chemicals and materials," said Don Millard, head of the NSF Directorate for Engineering. "This partnership will allow researchers to investigate new ideas for biomanufacturing, test and improve new methods at scale, and ultimately make biotechnology advances widely available." 


“We’re grateful to the National Science Foundation for their partnership and investment in these projects,” said Melanie Tomczak, Chief Technology Officer and Head of Programs at BioMADE. “BioMADE has always represented the power of collaboration, bringing together public, private, and government partners to enact change for the U.S. biomanufacturing industry. These projects are no different, and I look forward to seeing the wide-reaching effects that our members will have through this work.”   


Bioindustrial manufacturing uses biological systems to convert agricultural feedstocks and waste streams to high-value chemicals, materials, textiles, fuels and lubricants, bioplastics, composites, and other products for consumer and defense needs. Because bioindustrial manufacturing typically uses feedstocks such as corn, soy, and sugar beets, American farmers will benefit from the new markets created by BioMADE technologies, and rural communities will benefit from the manufacturing jobs creating the associated products.   


As the U.S. competes for global leadership in this growing industry, these new projects will move the needle by scaling up production of needed products, improving processes that span the industry, and building the needed workforce. 


Technology and Innovation Projects


6 projects | $4.6 million DoW funds | $2.2 million NSF funds | $4.8 million non-federal cost share   Federal funding from the U.S. Department of War and the U.S. National Science Foundation 


  • Optimizing Lithium Release and Recovery for Cost-Effective Biomining Processes – This project will develop and validate a scalable microbial process for extracting lithium from produced water, a lithium-rich industrial byproduct generated during oil and gas production. 
    Member:     AlkaLi Labs
  • Driving Cost Reduction in Biomanufacturing Biomaterials from Methane: Engineering Novel Strains to Increase Downstream Processing Efficiency – By increasing the efficiency of downstream processing, this project will reduce costs and improve overall process economics to produce PHA from methane gas for use in films, fibers, and 3D printing.   
    Member team:     Mango Materials, University of California, Davis
  • Development of Genomic Language Models to Predict Optimal Genomes for Commercial Protein Production – This project will create a first-of-its-kind predictive AI model that will accelerate strain optimization for the production of resilient and cost-effective proteins capable of wound healing, advanced nutrition, chemical defense, or other defense-relevant compounds.
    Member team:     Triplebar, University of California, Berkeley
  • In-Fermenter Cell Datastreams: Wireless Networks of Free-Floating Microbial-Electronic Sensors – Using a network of in-bioreactor free-floating sensors, this project will generate a new type of datastream from industrial bioreactors to enable predictive artificial intelligence (AI) and machine learning (ML) for fermentation optimization.
    Member team:     Boston University, Capra Biosciences
  • Cell Cultured Chocolate – Through novel bioreactors, improved vessel and media sterilization methods, and in-line biomass sensors, this project will lower the production costs of high-quality chocolate products by using cacao plant cell culture.
    Member team:     University of California – Davis, California Cultured
  • Low-Cost Nanobody-Based Growth Factor Replacements – This project will develop scalable, low-cost manufacturing methods for next-generation media additives that could enable distributed production and deployment for diagnostics and countermeasures in response to new disease outbreaks warfighters may be experiencing around the world, as well as protecting everyday Americans.   
    Member team:     Roke Biotechnologies, Duke University


Education and Workforce Development Projects


6 projects   $4.4 million federal funds   $5.2 million non-federal cost share   Federal funding from the U.S. Department of War 


  • How To Grow (Almost) Anything: A National Network for Enabling and Scaling EWD in Biomanufacturing – This project will train the next generation of bioindustrial manufacturing talent by creating and implementing a custom curriculum that will include hands-on lab modules, weekly lectures, and individual and network-wide final projects that reflect current and emerging needs in the bioindustrial manufacturing sector.
    Member:     Massachusetts Institute of Technology
  • Apprenticeship Framework for Pilot-Scale Bioindustrial Manufacturing Operator Training – By developing an apprenticeship training program for biomanufacturing operators in a pilot plant environment, this work will result in trained apprentices and a blueprint to translate the apprenticeship program to other facilities across the U.S.
    Member team:     Manus, University of Georgia
  • DESIGN of a Biomanufacturing EWD Prototype to Support the Growth of South Dakota's Bioeconomy – This pilot-scale biomanufacturing education and workforce development training program will create course content for people at all levels interested in a career in biomanufacturing, including veterans re-entering the civilian workforce.
    Member team:     Dakota BioWorx, South Dakota Biotech
  • NC BioMISSION – After partnering with industry to build a robust curriculum, this project will launch an undergraduate certificate program, provide a capstone industry experience, and integrate data analytics, data science, and machine learning for biomanufacturing. 
    Member:     University of North Carolina, Greensboro
  • SPRINT: Scalable Protein Research for INnovative Training – This project will expand, implement, and publicly share a scalable biomanufacturing training model to prepare thousands of undergraduate students for careers in the bioindustrial manufacturing economy. 
    Member team:     University of California – Davis, MiraCosta College, Modesto Junior College
  • Strengthening the Life Science Talent Pipeline: Life Science Career Fellowship Personalized Cohort – By working with multiple community colleges in Los Angeles and the Bay Area, this project will provide comprehensive career preparation through personalized industry mentorship, professional development workshops, networking opportunities, and company tours.
    Member team:     Biocom Institute


Safety and Security Projects 


2 projects   $131,000 federal funds   $131,000 non-federal cost share   Federal funding from the U.S. Department of War 


  • Development of Biopesticide Life Cycle Analysis Resources – Researchers will create a comprehensive Life Cycle Assessment and Life Cycle Inventory Data Gap Framework for a representative biopesticide that will include critical data and tools to understand and reduce detrimental impacts throughout the bioproduct life cycle—from raw material sourcing to production and end use. 
    Member team:     Boundless Impact Research & Analytics,Invasive Species Corporation
  • Resilient Domestic Feedstocks for the U.S. Precision Fermentation Industry – This project will improve domestic bioindustrial manufacturing outcomes and increase its competitiveness through enhanced Life Cycle Assessments (LCA) of feedstocks. 
    Member:     Checkerspot


About BioMADE


BioMADE and its network of over 300 members across 40 states are strengthening American competitiveness, creating a more resilient supply chain, reshoring manufacturing jobs, producing biobased products without relying on foreign inputs, and building a globally competitive 21st century workforce. BioMADE is also launching a Pilot Plant Network of critically needed pilot-scale bioindustrial manufacturing facilities that will propel products out of the lab and into the commercial and defense markets. BioMADE was catalyzed by the U.S. Department of Defense in October of 2020 and is a proud member of Manufacturing USA®. Learn more about BioMADE at biomade.org.  


Source: https://www.biomade.org/news/biomade-announces-214-million-invested-in-14-projects

Nutrivert announces first close on $6 million Series A-2 funding round

April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.

USDOL Approves National Biomanufacturing Technician Standards

April 16, 2026
[Seattle, WA] April 15, 2026 – Apprenti, the leading national intermediary for Registered Apprenticeship (RA), is proud to announce the formal approval and filing of the National Biomanufacturing Technician Standards with the U.S. Department of Labor (USDOL). Crafted under the strategic guidance of the Apprenti Life Science Advisory Board—which includes leaders from Pfizer, Merck, Thermo Fisher, and Biogen—these standards were developed in close partnership with the Life Sciences Workforce Collaborative (LSWC) and InnovATEBIO as part of a high-impact NIIMBL project. This approval represents a foundational shift for the industry, moving away from a fragmented, state-by-state approach to a scalable, consistent model for developing biomanufacturing professionals at sites across all 50 states. The national standards provide a “plug-and-play” framework that ensures a technician trained in Massachusetts or North Carolina meets the same rigorous, industry-vetted benchmarks as one in Ohio or Missouri. The foundational development of these national standards was informed by existing Life Science RA programs from organizations across the country, including: MassBioEd, Oregon Life Sciences, National Center for Therapeutics Manufacturing (NCTM), BioSTL, Wistar Institute, North Carolina Life Sciences Apprenticeship Consortium (NCLSAC) and others. A National Engine for Talent: The filing of these standards is a cornerstone of NIIMBL’s efforts to strengthen domestic biomanufacturing capabilities and develop the workforce of the future. Beyond the standards themselves, the project is delivering a suite of resources and tools—including a comprehensive Employer Toolkit and specialized screening rubrics—that state-based organizations and employers can leverage to implement RA programming for their most in-demand roles. “These national standards set the stage for a sustainable, skills-first pipeline that mirrors the rigor of the industry’s most complex manufacturing processes,” said Daniel Weagle, Director of Life Science Business Development at Apprenti. “By providing a unified approach, we are empowering national employers to scale their workforce development efforts strategically and accessibly.” The Value Proposition of Registered Apprenticeship For Life Science employers, the Registered Apprenticeship model offers a compelling business case rooted in cost-effectiveness and long-term stability: High Retention: RA programs boast exceptional retention rates—historically as high as 89% to 90%—as apprentices are trained within a company’s specific culture and protocols from day one. Cost Efficiency: Research indicates that for every dollar spent on apprenticeship, employers see an average return of $1.47 in increased productivity and reduced recruitment costs. Inclusive Innovation: The model expands access to untapped talent pools, including non-degreed individuals and career-switchers, ensuring the biomanufacturing workforce reflects the demographics of the communities it serves. As the global biopharmaceutical market is projected to exceed $570 billion by 2032 , this partnership between Apprenti, NIIMBL, and industry leaders ensures that the U.S. workforce is not just prepared for the future of manufacturing, but is actively driving it. This project was developed with an award from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance from the U.S. Department of Commerce, National Institute of Standards and Technology (70NANB21H086). About Apprenti: Apprenti is a 501(c)(3) nonprofit organization and a U.S. Department of Labor recognized Intermediary. Apprenti designs and delivers scalable Registered Apprenticeship (RA) programs in high-demand industries. By adapting the proven apprenticeship model, Apprenti helps employers meet workforce needs while training the next generation of skilled professionals. Apprenti’s programs are industry-recognized, federally approved, and supports employers across the country. Since launching in 2015, Apprenti has partnered with employers, government agencies, and education providers to create new apprenticeship pathways. About NIIMBL The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of industry standards, and educate a world-leading workforce. Media Contact: Dan Maiese, Communications Manager, dmaiese@niimbl.org , 302-831-3824 About the Life Sciences Workforce Collaborative (LSWC) The Life Sciences Workforce Collaborative (LSWC) is a national nonprofit coalition of state, regional and national life science associations and institutes who are working together to build a competitive, and future-ready life sciences workforce. Originally founded in 2012 as the Coalition of State Bioscience Institutes (CSBI), LSWC connects industry, academia, and government partners through data-driven insights, best practice sharing, and collaborative programs. Learn more at www.LifeSciencesWorkforce.org About InnovATEBIO InnovATEBIO is a National Center for Biotechnology Education, working to advance the education of highly skilled technicians for the nation’s biotechnology workforce. Toward this goal, InnovATEBIO provides leadership in biotechnology technician education, including support for development and sharing of best practices and emerging technologies in biotechnology workforce development. Read LSWC's full announcement here.

BIO Statement on the Section 232 Pharmaceutical Proclamation

April 4, 2026
April 2, 2026- WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) , released the following statement on Section 232 Pharmaceutical Proclamation. “A thriving American biotechnology ecosystem is essential to growing the U.S. economy, strengthening national security, and improving the health and well‑being of everyday Americans. While we appreciate the Administration’s recognition of the need for tariff exemptions for certain critical biotech products, the reality is that any tariffs on America’s medicines will raise costs, impede domestic manufacturing, and delay the development of new treatments - all while doing nothing to enhance our national security. “U.S. biotech companies have been eager to expand investments here at home, but tariffs, along with an uncertain policy environment and efforts to force “most‑favored nation” schemes, work directly against that goal. The risks are especially acute for small and mid‑size biotech companies, which develop more than half of all FDA‑approved medicines yet often lack the capital to build dedicated manufacturing facilities as they weather an industry defined by high costs, long development timelines, and significant risk. “The fact is: tariffs divert scarce resources away from research and development, weaken American biotech against China’s rising industry, and ultimately, harm health and economic wellbeing of Americans. “We stand ready to work with the Administration on a long‑term strategy that encourages biotechnology investment, reduces the time, cost, and uncertainty of developing new medicines, expands U.S. biomanufacturing capacity, and ensures American innovation is fairly valued overseas. Tariffs and MFN are not the answer." Source - https://www.bio.org/press-release/bio-statement-section-232-pharmaceutical-proclamation
MORE POSTS